

USE OF FAMPRIDINE IN MULTIPLE SCLEROSIS PATIENTS

Onteniente González A, Martín Blas C, Liras Medina A, Vázquez Sánchez R,

Sánchez-Rubio Ferrandez J, Molina García T. Hospital Universitario de Getafe, Madrid, Spain

1 BACKGROUND

Fampridine is a drug indicated to improve walking in adult patients with multiple sclerosis (MS). Patients should be evaluated after two weeks and treatment should be stopped for those who have not shown any improvement.

2 PURPOSE

To evaluate walking improvement in multiple sclerosis patients treated with Fampridine and compliance with drug stopping criteria at two weeks.

3 METHODS

Retrospective study in MS patients treated with Fampridine (Jan/2014– Sept/2014). Timed 25-Foot Walk (T25FW) and Twelve Item MS Walking Scale (MSWS-12) were used to evaluate drug response. Data recorded were age, gender, and results of T25FW and MSWS-12 at baseline and after two weeks of treatment. Drug discontinuation in non-responders was evaluated. Means were calculated and comparisons were performed by using Wilcoxon Signed Rank test.


4 RESULTS

- ❖ 10 adult MS patients were included in the study (40% male; mean age 55±9.7 years).
- ❖ 90% improved their walking tests.
- ❖ There was only one non-responder patient who did not stop drug treatment.

MSWS-12	
<u>Significant Improvement</u>	<u>No difference</u>
Balance ($p \leq 0.05$)	Ability to run ($p = 0.317$)
Time standing ($p \leq 0.05$)	Need for using a walking support outdoors ($p = 0.590$) or indoors ($p = 0.157$)
Walking speed and Distance ($p \leq 0.05$)	

Multiple Sclerosis Walking Scale (MSWS-12)					
Instructions:					
• These questions ask about limitations to your walking due to MS during the past 2 weeks.					
• For each statement, please circle the one number that best describes your degree of limitation.					
• Please answer all questions even if some seem rather similar to others, or seem irrelevant to you.					
• If you cannot walk at all, please tick this box: ☐					
In the past two weeks, how much has your MS...	Not at all	A little	Moderately	Quite a bit	Extremely
1. Limited your ability to walk?	1	2	3	4	5
2. Limited your ability to run?	1	2	3	4	5
3. Limited your ability to climb up and down stairs?	1	2	3	4	5
4. Made standing when doing things more difficult?	1	2	3	4	5
5. Limited your balance when standing or walking?	1	2	3	4	5
6. Limited how far you are able to walk?	1	2	3	4	5
7. Increased the effort needed for you to walk?	1	2	3	4	5
8. Made it necessary for you to use support when walking indoors (e.g., holding on to furniture, using a stick, etc.)?	1	2	3	4	5
9. Made it necessary for you to use support when walking outdoors (e.g., using a stick, a frame, etc.)?	1	2	3	4	5
10. Slowed down your walking?	1	2	3	4	5
11. Affected how smoothly you walk?	1	2	3	4	5
12. Made you concentrate on your walking?	1	2	3	4	5

T25FW		P<0.05
Initially	After 2 weeks	
12.2s ±5.9	8.96s ±3.8	



5 CONCLUSIONS

- ✓ Most patients on Fampridine improve walking at two weeks especially regarding balance, distance and time standing.
- ✓ Stopping criteria was not observed in a non-responder patient.